ESR1 and breast cancer: The majority (>60%) of breast cancers are ER-positive [1], whereas about 20% are negative for ER, PR, and HER2 expression (that is triple-negative breast cancer, TNBC) and most of these cancers have unfavorable clinical prognosis [2].